Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.

BACKGROUND

Gefitinib remains an excellent treatment option for patients with a variety of cancers, including non small cell lung cancer (NSCLC). However, clinicians must be aware of the potential of gefitinib to cause an inflammatory reaction in the skin, lungs and bladder.

CASE PRESENTATION: We present a case on hemorrhagic cystitis and severely contracted bladder in a patient with NSCLC on gefitinib.

CONCLUSIONS

Further studies are needed to substantiate the association of gefitinib therapy with hemorrhagic cystitis and contracted bladder.